Active Ingredient History

  • Now
Aleglitazar is a peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes. It is no longer in phase III clinical trials.   Wikipedia

  • SMILES: CO[C@@H](Cc1ccc(OCCc2nc(oc2C)c3ccccc3)c4ccsc14)C(=O)O
  • Mol. Mass: 437.52
  • ALogP: 5.13
  • ChEMBL Molecule:
More Chemistry
aleglitazar | r-1439 | ro-0728804


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue